Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Small Cell Lung Carcinoma 9Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neutropenia 1Neoplasm Metastasis 1NSCLC 1Limited Stage Small Cell Lung Cancer 1Endometrial Neoplasms 1Breast Neoplasms 1Advanced Squamous Non-Small-Cell Lung Cancer 1

Interventions

pembrolizumab 30Nivolumab 12Carboplatin 6atezolizumab 5Trastuzumab 5aldesleukin 4Specimen Handling 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4Cisplatin 4Bevacizumab 4spartalizumab 3fludarabine 3durvalumab 3Polymerase Chain Reaction 3Irinotecan 3Interleukin-2 3Gene Expression Profiling 3Blood Specimen Collection 3Biopsy 3zimberelimab 2tisotumab vedotin 2tislelizumab 2sargramostim 2osimertinib 2enzalutamide 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × trilaciclib × Thoracic × Clear all
NCT06297811 2024-03-07

Myeloprotection With Trilaciclib in Pan-cancer Population

Sun Yat-sen University

Phase 2 Not yet recruiting
132 enrolled
BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡